![](https://endpts.com/wp-content/uploads/2021/10/Sunao-Manabe-Daiichi-Sankyo-tile-scaled.jpg)
Sunao Manabe, Daiichi Sankyo CEO
Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail
Driven by a series of wins for its antibody-drug conjugate pipeline, Daiichi Sankyo has earned a reputation as an ADC expert with a successful partnership …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.